Panbela Therapeutics, Inc. PBLA · Stock Open Panbela Therapeutics, Inc. in new tab
Panbela Therapeutics, Inc. Analysis (PBLA)
Is Panbela Therapeutics, Inc. a good investment? Panbela Therapeutics, Inc. (PBLA) is currently trading at 0.000200 USD.
Earnings Schedule: Panbela Therapeutics, Inc. is expected to release its next earnings report on Nov. 13, 2026. The market consensus estimate for Forward EPS is -5.66.
Investor FAQ
Does Panbela Therapeutics, Inc. pay a dividend?
No, it does not currently pay a dividend.
What asset class is Panbela Therapeutics, Inc.?
Panbela Therapeutics, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be Nov. 13, 2026. The company currently has a trailing EPS of -34.51.
Company Profile
Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of disruptive therapeutics for the treatment of patients with urgent unmet medical needs. The company's lead product candidates are Ivospemin (SBP-101), a proprietary polyamine analogue, which has completed Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma; Flynpovi, a combination of eflornithine (CPP-1X) and sulindac which is in Phase III clinical trials; and Eflornithine, an enzyme-activated irreversible inhibitor of the enzyme ornithine decarboxylase, currently under Phase I/II trial. It has a research agreement with the Johns Hopkins University School of Medicine for the development of ivospemin. The company was formerly known as Sun BioPharma, Inc. and changed its name to Panbela Therapeutics, Inc. in December 2020. Panbela Therapeutics, Inc. was incorporated in 2011 and is based in Waconia, Minnesota.
| Split Date | Split Ratio to 1 |
|---|---|
| Nov. 8, 2017 | 1:10 |
| Jan. 13, 2023 | 0.03 |
| June 1, 2023 | 0.03 |
| Jan. 18, 2024 | 1:20 |
Community Discussion